Literature DB >> 16487512

Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon.

Mehmet O Kilinc1, Lata Mukundan, Esma S Yolcu, Narendra P Singh, Jill Suttles, Haval Shirwan.   

Abstract

Effective aggregation of cell surface immune receptors with their ligands is critical in promoting humoral and cellular immune responses. Simulation of these interactions using soluble multimeric ligands having potent adjuvant effects may prove an effective alternative to agonistic antibodies as immunotherapeutics. Multimeric ligands may effectively engage their receptors, leading to aggregation and effective signal transduction. We exploited the structural characteristics of streptavidin (SA) for the generation of multimeric chimeric proteins. Streptavidin forms stable tetramers and oligomers under physiological conditions, and, as such, chimeric molecules with SA are expected to possess similar features. Two chimeric molecules consisting of the extracellular domains of human and mouse CD40L and a modified form of core streptavidin were generated. These proteins form stable oligomers that could only be dissociated into monomers by heating at 100 degrees C, but not 60 degrees C, under denaturing conditions. The chimeric proteins vigorously stimulated B cells, monocytes, and dendritic cells for the production of cytokines and chemokines and upregulation of immunostimulatory molecules. The use of SA as a chaperon presents a novel approach to generate multimeric immunological molecules with potent activities and their use as potential therapeutics for the treatment of cancer and other immune-based disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487512     DOI: 10.1016/j.yexmp.2005.12.004

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

1.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

2.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 3.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

4.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Authors:  Rajesh K Sharma; Kutlu G Elpek; Esma S Yolcu; Rich-Henry Schabowsky; Hong Zhao; Laura Bandura-Morgan; Haval Shirwan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

5.  A new method to customize protein expression vectors for fast, efficient and background free parallel cloning.

Authors:  Judith Scholz; Hüseyin Besir; Claudia Strasser; Sabine Suppmann
Journal:  BMC Biotechnol       Date:  2013-02-14       Impact factor: 2.563

6.  Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy.

Authors:  R K Sharma; E S Yolcu; K G Elpek; H Shirwan
Journal:  Cancer Gene Ther       Date:  2010-06-18       Impact factor: 5.987

7.  Characterization of iNOS(+) Neutrophil-like ring cell in tumor-bearing mice.

Authors:  Lauren P Virtuoso; Jamie L Harden; Paula Sotomayor; Wade J Sigurdson; Fuminobu Yoshimura; Nejat K Egilmez; Boris Minev; Mehmet O Kilinc
Journal:  J Transl Med       Date:  2012-07-30       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.